Today: 12 April 2026
Palantir stock slips despite Citi upgrade as Feb. 2 earnings loom
13 January 2026
1 min read

Palantir stock slips despite Citi upgrade as Feb. 2 earnings loom

New York, January 13, 2026, 10:42 ET — Regular session

  • Palantir shares slipped roughly 1.2% in morning trading, underperforming the broader U.S. benchmarks, which fell about 0.4%
  • Citi upgrades its rating to Buy and boosts the target price to $235
  • Palantir will release its fourth-quarter results after the market closes on Feb. 2

Palantir Technologies Inc. shares dropped roughly 1.2% to $177.22 Tuesday morning, lagging a mild pullback in U.S. stocks. The software company is buoyed by an analyst upgrade, while investors keep a close watch on its upcoming earnings release.

Citi analyst Tyler Radke raised Palantir to Buy from Neutral and boosted his price target to $235 from $210, citing a pickup in enterprise demand and the possibility of a government defense spending “supercycle.” Citi forecasts Palantir could see 70% to 80% revenue growth by 2026. “We are upgrading PLTR to Buy/High-Risk from Neutral and raising estimates,” the note said, per Seeking Alpha. TipRanks

Palantir announced Monday it will release its fourth-quarter and full-year 2025 results after the market closes on Feb. 2. The stock’s sharp rally has sent its valuation into unusual territory, setting up the upcoming earnings as a key check on whether demand can sustain that momentum.

Radke’s argument hinges on moving beyond pilot projects to full-scale rollouts, especially in sectors like healthcare and defense, along with broader adoption of Palantir’s Artificial Intelligence Platform, or AIP. Simply put, the expectation is that initial trials will convert into sizable repeat contracts that noticeably boost revenue.

Palantir announced it will hold a webcast at 5 p.m. ET and respond to shareholder questions via an online portal. The company did not release any preliminary results in the statement.

Palantir provides software that helps government agencies and companies integrate and analyze data. The company has been ramping up efforts with commercial clients but still relies heavily on its sizable government contracts, which can fluctuate with their timing.

Tuesday’s drop makes it clear the market isn’t handing out freebies after the upgrade. Over the past year, investors have been willing to pay a premium for firms linked to enterprise AI spending, and Palantir is one of those stocks where the key question is how much of that optimism is already baked in.

Still, the setup works both ways. The stock trades at a hefty premium to the broader market, so a stumble in growth, margins, or deal conversion rates could quickly weigh on the shares—even if the long-term outlook remains unchanged.

Investors are focused on whether commercial momentum holds steady and any updates on government demand along with its pipeline. Expect guidance to carry more weight than the headline numbers for the quarter.

Palantir’s next major event is Feb. 2, with the earnings report coming after the market closes and a webcast scheduled for later that night.

Stock Market Today

  • CGI (TSX:GIB.A) Shares Slide, Valuation Points to 36% Undervaluation Amid Revenue Growth
    April 11, 2026, 7:17 PM EDT. CGI's (TSX:GIB.A) share price fell 6.3% in 7 days and 26.18% over 90 days, dragging its one-year total shareholder return down by 31.48%. Despite this weakness, the company reports multibillion-dollar revenue and profit, supported by a $30.6 billion backlog and growing demand in digital modernization and managed services. Analyst models suggest CGI is undervalued by about 36%, with a fair value estimate of CA$151.15 versus a closing price of CA$96.51. Risks include potential macroeconomic delays on large contracts and acquisition integration challenges. Investors are advised to analyze earnings, margin prospects, and broader opportunities in tech and automation before deciding.

Latest article

India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

11 April 2026
Lockheed Martin said it is not in direct talks with India over the F-35, clarifying that any approach must go through official U.S. and Indian channels under the Foreign Military Sales process. Indian officials confirmed no formal discussions on acquiring the F-35 have begun. India recently approved a $40 billion military upgrade, including other fighter jets, while Lockheed’s F-21 remains in a separate competition.
Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

11 April 2026
Snowflake shares fell 8.4% to $121.11 on Friday after an 11.7% drop Thursday, as investors sold off software stocks amid concerns over new AI tools from Anthropic and OpenAI. The stock now trades just above its 52-week low. The S&P 500 Software and Services Index is down 25.5% for the year. Snowflake reported fourth-quarter product revenue of $1.23 billion, up 30% from a year earlier.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 7:22 PM EDT CGI (TSX:GIB.A) Shares Slide, Valuation Points to 36% Undervaluation Amid Revenue Growth April 11, 2026, 7:17 PM EDT. CGI's (TSX:GIB.A) share price fell 6.3% in 7 days and 26.18% over 90 days, dragging its one-year total shareholder return down by 31.48%. Despite this weakness, the company reports multibillion-dollar revenue and profit, supported by a $30.6 billion backlog and growing demand in digital modernization and managed services. Analyst models suggest CGI is undervalued by about 36%, with a fair value estimate of CA$151.15 versus a closing
Oracle stock slips in regular trade despite Goldman buy call as AI buildout stays in focus
Previous Story

Oracle stock slips in regular trade despite Goldman buy call as AI buildout stays in focus

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next
Next Story

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

Go toTop